Evidence map›Paper›PMID 25531344›Full record

ArticleViral immunology2015

Multiple circulating infections can mimic the early stages of viral hemorrhagic fevers and possible human exposure to filoviruses in Sierra Leone prior to the 2014 outbreak.

Matthew L Boisen, John S Schieffelin, Augustine Goba, Darin Oottamasathien, Abigail B Jones, Jeffrey G Shaffer, Kathryn M Hastie, Jessica N Hartnett, Mambu Momoh, Mohammed Fullah and 24 more

Open access · greenAbstract read
In one paragraph

Article in Viral immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 3 pooled it
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Review
  7. The Threat of Vector-Borne Diseases in Sierra Leone.The American journal of tropical medicine and hygiene · 2023
    Review
  8. Lassa Fever Natural History and Clinical Management.Current topics in microbiology and immunology · 2023
    Article
  9. Article
  10. Article
  11. Article
  12. Lassa fever diagnostics: past, present, and future.Current opinion in virology · 2019
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. An Outbreak of Ebola Virus Disease in the Lassa Fever Zone.The Journal of infectious diseases · 2016
    Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors at 8 institutions in 1 country.

Matthew L Boisen1 Corgenix Medical Corporation, Inc. , Broomfield, Colorado.
John S Schieffelin
Augustine Goba
Darin Oottamasathien
Abigail B Jones
Jeffrey G Shaffer
Kathryn M Hastie
Jessica N Hartnett
Mambu Momoh
Mohammed Fullah
Michael Gabiki
Sidiki Safa
Michelle Zandonatti
Marnie Fusco
Zach Bornholdt
Dafna Abelson
Stephen K Gire
Kristian G Andersen
Ridhi Tariyal
Mathew Stremlau
Robert W Cross
Joan B Geisbert
Kelly R Pitts
Thomas W Geisbert
Peter Kulakoski
Russell B Wilson
Lee Henderson
Pardis C Sabeti
Donald S Grant
Robert F Garry
Erica O Saphire
Luis M Branco
Sheik Humarr Khan
Viral Hemorrhagic Fever Consortium
Scripps Research Institute · USTulane University · USBroad Institute · USCorixa Corporation · USAutoimmune Technologies (United States) · USThe University of Texas Medical Branch at Galveston · USKALGEn Consultants (United States) · USSimBiotic Software (United States) · US

Funding

Regulatory Compliance Core - Galveston National Laboratory BSL4 OperationsUC7AI094660 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI DAVID BEASLEY · 2011 to 2026
$208.8M
Health, Safety and Training ServicesUC7AI070083 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI HOLBROOK, MICHAEL R · 2006 to 2010
$49.5M
Mechanistic Virology CoreU19AI109762 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI SAPHIRE, ERICA OLLMANN · 2014 to 2018
$29.6M
Preclinical development of recombinant antigen diagnostics for Lassa feverU01AI082119 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI GARRY, ROBERT F · 2009 to 2013
$6.7M
Antibody immunotherapeutics for biodefense against Lassa virusR01AI104621 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI GARRY, ROBERT F · 2013 to 2017
$5.8M
Recombinant antigen assays for Lassa and other arenaviruUC1AI067188 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI GARRY, ROBERT F · 2005 to 2005
$3.9M
Project 2. Expansion of Clinical Research Capacity at Kenema Government HospitalU19AI115589 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI GARRY, ROBERT F · 2015 to 2019
$3.6M
Recombinant antigen diagnostics for filovirusesR44AI088843 · NIAID · ZALGEN LABS, LLC · PI BOISEN, MATTHEW L · 2014 to 2016
$3.0M
NIAID NIH HHS AI067188NIAID NIH HHS AI082119NIAID NIH HHS R01 AI104621NIAID NIH HHS R44 AI088843NIAID NIH HHS U19 AI109762NIAID NIH HHS U19 AI115589NIAID NIH HHS UC7 AI070083NIAID NIH HHS UC7 AI094660
6 · The paper itself

Abstract

Lassa fever (LF) is a severe viral hemorrhagic fever caused by Lassa virus (LASV). The LF program at the Kenema Government Hospital (KGH) in Eastern Sierra Leone currently provides diagnostic services and clinical care for more than 500 suspected LF cases per year. Nearly two-thirds of suspected LF patients presenting to the LF Ward test negative for either LASV antigen or anti-LASV immunoglobulin M (IgM), and therefore are considered to have a non-Lassa febrile illness (NLFI). The NLFI patients in this study were generally severely ill, which accounts for their high case fatality rate of 36%. The current studies were aimed at determining possible causes of severe febrile illnesses in non-LF cases presenting to the KGH, including possible involvement of filoviruses. A seroprevalence survey employing commercial enzyme-linked immunosorbent assay tests revealed significant IgM and IgG reactivity against dengue virus, chikungunya virus, West Nile virus (WNV), Leptospira, and typhus. A polymerase chain reaction-based survey using sera from subjects with acute LF, evidence of prior LASV exposure, or NLFI revealed widespread infection with Plasmodium falciparum malaria in febrile patients. WNV RNA was detected in a subset of patients, and a 419 nt amplicon specific to filoviral L segment RNA was detected at low levels in a single patient. However, 22% of the patients presenting at the KGH between 2011 and 2014 who were included in this survey registered anti-Ebola virus (EBOV) IgG or IgM, suggesting prior exposure to this agent. The 2014 Ebola virus disease (EVD) outbreak is already the deadliest and most widely dispersed outbreak of its kind on record. Serological evidence reported here for possible human exposure to filoviruses in Sierra Leone prior to the current EVD outbreak supports genetic analysis that EBOV may have been present in West Africa for some time prior to the 2014 outbreak.

Indexed as

Disease OutbreaksAntibodies, BacterialAntibodies, ViralDNA, ProtozoanEnzyme-Linked Immunosorbent AssayHemorrhagic Fevers, ViralHumansImmunoglobulin GImmunoglobulin MPolymerase Chain ReactionRetrospective StudiesRNA, ViralSeroepidemiologic StudiesSierra LeoneAntibodies, BacterialAntibodies, ViralDNA, ProtozoanImmunoglobulin GImmunoglobulin MRNA, Viral

Identifiers

PMID25531344
PMCPMC4287116
OpenAlexW2043670145

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.